Conditions: Solid Tumor or Lymphoma
Keywords: Resistant and refractory solid tumors lymphomas hodgkins disease non-hodgkins lymphoma neoplasms
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 82
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.

Detailed description:
This is an open-label, non-randomized, dose escalation study. Patients will be treated with lenvatinib once daily. Each four-week treatment period will be considered to be one treatment cycle. The selection of subsequent dose levels will be performed according to an accelerated design: Although initially 3 patients per dose level will be entered, the next dose level can be opened for patient accrual after only the first patient in the previous cohort completes Cycle 1 with no drug-related toxicity greater than grade 1 (except alopecia, lymphopenia and anemia).

Arms:
arm 1: None

Interventions: intervention 1: Lenvatinib
Intervention descriptions: intervention 1: Lenvatinib tablets taken orally, once daily.

Protocol document: